We claim:

1. A therapeutic composition comprising:

a) an isolated human monoclonal IgG antibody that binds specifically to the Kunitz 1 and Kuntiz 2 domain of tissue factor pathway inhibitor (TFPI).

2. The composition of claim 1, wherein the antibody heavy chain has a CDR-1 region comprised of an amino acid sequence having at least 80% homology with SEQ ID NO. 305, a CDR-2 region comprised of an amino acid sequence having at least 80% homology with SEQ ID NO. 348, and a CDR-3 region comprised of an amino acid sequence having at least 80% homology with SEQ ID NO. 391.

3. The composition of claim 1 further comprising Factor VIII or Factor IX in the substantial absence of Factor VII.

4. The composition of claim 1, wherein the antibody has a binding affinity to human TFPI by Biacore assay of about 1.25 to 1140 nM.

5. The composition of claim 1 wherein the antibody is formulated in combination a dose of 10 to 100 mg in a pharmaceutically acceptable carrier for injection.

6. The composition of claim 1, wherein the CDR-2 region has at least 85% homology to SEQ IDNO. 348.

7. The composition of claim 1, wherein the CDR-3 region has at least 85% homology to SEQ ID NO. 391.

8. The composition of claim 1, wherein the antibody is a fragment of a single chain.

9. The composition of claim 1, wherein the antibody heavy chain has a CDR-1 region comprised of an amino acid sequence as shown in SEQ ID NO. 305, a CDR-2 region comprised of an amino acid sequence as shown in SEQ ID NO. 348, and a CDR-3 region comprised of an amino acid sequence as shown in SEQ ID NO. 391.

10. The composition of claim 1, wherein the antibody heavy chain has a CDR-1 region comprised of an amino acid sequence as shown in SEQ ID NO. 305, a CDR-2 region comprised of an amino acid sequence as shown in SEQ ID NO. 348 and a CDR-3 region comprised of an amino acid sequence as shown in SEQ ID NO. 39 1, and wherein the antibody light chain has CDR-1 region comprised of an amino acid sequence as shown in SEQ ID NO. 176, a CDR-2 region comprised of an amino acid sequence as shown in SEQ ID NO. 219 and a CDR-3 region comprised of an amino acid sequence as shown in SEQ ID NO. 262.

11. The composition of claim 1, wherein the antibody heavy chain is comprised of an amino acid sequence as shown in SEQ ID NO. 16.

12. The composition of claim 8, wherein the light chain is comprised of an amino acid sequence as shown in SEQ ID NO. 14.

13. The composition of claim 1, wherein the antibody has a binding affinity to human TFPI by Biacore assay of about 1.25 nM.

14. The composition of claim 3, wherein the composition formulated in a dose of 10 to 100 mg of the human antibody in a pharmaceutically acceptable carrier for injection.

15. A therapeutic composition comprising in combination:

a) an isolated human monoclonal IgG antibody that binds specifically to the Kunitz 1 and Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), and wherein the antibody heavy chain has a CDR-1 region comprised of an amino acid sequence having at least 80% homology with SEQ ID NO. 341, a CDR-2 region comprised of an amino acid sequence having at least 80% homology with SEQ ID NO. 384, and a CDR-3 region comprised of an amino acid sequence having at least 80% homology with SEQ ID NO. 427.

16. The composition of claim 15, further comprising Factor VIII or Factor IX in the substantial absence of Factor VII.

17. The composition of claim 16, wherein the antibody has a binding affinity to human TFPI by Biacore assay of about 15.7 nM.

18. The composition of claim 16, wherein the composition is formulated in a dose of 10 to 100 mg of the human antibody in a pharmaceutically acceptable carrier for injection.

19. The composition of claim 15, whereas the CDR-1 region has at least 85% homology to SEQ ID NO. 341.

20. The composition of claim 15, wherein the CDR-2 region has at least 85% homology to SEQ ID NO. 384.

21. The composition of claim 15, wherein the CDR-3 region has at least 85% homology to SEQ ID NO. 427.

22. The composition of claim 15, wherein the antibody heavy chain has a CDR-1 region comprised of an amino acid sequence as shown in SEQ ID NO. 341, a CDR-2 region comprised of an amino acid sequence as shown in SEQ ID NO. 384 and a CDR-3 region comprised of an amino acid sequence as shown in SEQ ID NO. 427.

23. The composition of claim 15, wherein the antibody heavy chain is comprised of an amino acid sequence as shown in SEQ ID NO. 160.

24. The composition of claim 15, wherein the antibody heavy chain has a CDR-1 region comprised of an amino acid sequence as shown in SEQ ID NO. 341, a CDR-2 region comprised of an amino acid sequence as shown in SEQ ID NO. 384 and a CDR-3 region comprised of an amino acid sequence as shown in SEQ ID NO. 427, and wherein the antibody light chain has CDR-1 region comprised of an amino acid sequence as shown in SEQ ID NO. 212, a CDR-2 region comprised of an amino acid sequence as shown in SEQ ID NO. 255 and a CDR-3 region comprised of an amino acid sequence as shown in SEQ ID NO. 298

25. The composition of claim 15, wherein the antibody heavy chain is comprised of an amino acid sequence as shown in SEQ ID NO. 160, and the antibody light chain is comprised of an amino acid sequence as shown in SEQ ID NO. 158.

26. A therapeutic composition comprising:

an isolated human monoclonal IgG antibody that binds specifically to the Kunitz 1 and the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), wherein the antibody heavy chain has a CDR-1 region comprised of an amino acid sequence having at least 80% homology to a sequence selected

from the group consisting of SEQ ID NOS. 302-344, a CDR-2 region comprised of an amino acid sequence selected from the group consisting of SEQ IDNOS. 345- 387, and CDR-3 region selected from the group consisting of SEQ ID NOS. 388-430.

27. The composition of claim ~~28~~26, wherein the antibody has a binding affinity to human TFPI by Biacore assay of about 1.25 to 1140 nM.

28. The composition of claim ~~28~~26, wherein the antibody ~~in~~is formulated in a dose of 10 to 100 mg in a pharmaceutically acceptable carrier for injection.

29. The composition of claim ~~28~~26, wherein the antibody light chain has CDR-1 region comprised of amino acid having at least about 80% homology to a sequence selected from the group consisting of SEQ ID NOS. 173-215, a CDR-2 region comprised of an amino acid sequence selected from the group consisting of SEQ ID NOS. 216-258, and a CDR-3 region selected from the group consisting of SEQ ID NOS. 259-301.

30. The use of ~~an~~ composition comprising an isolated human monoclonal IgG antibody of any of claims 1-29, for the manufacture of a medicament for treating a coagulation deficiency.

31. The use of ~~the antibody~~ claim 30, wherein the coagulation deficiency is hemophilia A or hemophilia B.

32. The use of claim 31 further comprising the Factor VIII or Factor IX in the substantial absence of Factor VII.